Hyderabad, Mar 31, 2015
Suven Life Sciences Ltd has secured three product patents for its new chemical entities in Canada, Japan and Korea.
The NCEs are associated with drugs useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia, the Hyderabad-based company said in a release issued here on Tuesday.
The company’s scrip gained 6.5 per cent and is trading at Rs. 297.80 on the Bombay Stock Exchange.
